Enter multiple symbols separated by commas

Genentech Shares Fall on Avastin Pricing Fears

Genentech shares traded lower on Thursday after data from a clinical trial indicated that a lower dosage of blockbuster cancer drug Avastin was as effective as the standard dose for lung cancer patients.

The South San Francisco, Calif.-based biotech giant announced this morning that data from a Phase III study showed that both the 15 mg/kg and 7.5 mg/kg dose of Avastin -- combined witih chemotherapy -- significantly improved survival in patients compared with chemotherapy alone.

These results are significant because current monthly costs for lung cancer patients taking Avastin are $8,800, according to Genentech. Analysts say this number could decrease significantly if the lower dose ultimately proves to be as effective as the larger one.

"We believe the success of the low dose arm will drive physicians to use to the lower, less expensive dose, in the majority of their lung cancer patients," said Credit Suisse biotech analyst Michael Aberman, in a report sent to investors Thursday.

"The impact of this change on our Avastin estimates for lung cancer is approximately $230 million per year at peak and a more modest $40 million this year," he said.

Aberman trimmed his price target on the shares to $83 from $84 and maintained a "neutral" rating on the stock.

"While we like Genentech as a company," Aberman said, "we think the stock will stay range-bound for 2007 as its growth is priced in and it faces pressures, including today’s results and competition from new entrants, e.g. GlaxoSmithKline's Tykerb."

The full results of the clincial trial, sponsored by majority shareholder and partner Roche, is expected to be released at the annual meeting of the American Society of Clinical Oncology, or ASCO, this June.

Avastin was approved in the United States for the treatment of non small-cell lung cancer last October.

Separately, health regulators yesterday said that Genentech's asthma drug Xolair should carry the strongest warning possible in order to alert doctors of the risk of a rare but serious reaction known as anaphylaxis.

Contact U.S. News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

  • Learning your value

    How to make sure you get what you¿re worth at your job, why you should stop apologizing, and how to manage work-life balance. Anchor Mika Brzeznski, author of the new book "Grow Your Value," shares her strategies for juggling busy lives.

  • Why women cheat?

    Is cheating bad? Why do women cheat? The founder and CEO of affair website Ashley Madison tells all, including why he has his eye on China.

  • Judge's gavel

    The Financial Industry Regulatory Authority disciplined several financial services firms and individuals in May 2015.

U.S. Video

  • Cramer: Here's a sign the market could rally

    Wall Street's been soaking in red, but "Mad Money" host Jim Cramer has one signal to watch for that could point to another run.

  • Burger war maneuvers

    Cramer looks at the number of company's selling burgers and tries to determine the quality names, as well as those to avoid.

  • Cramer: What's driving defense?

    Cramer says that even though President Obama has made it clear the US can no longer be the world's policeman, the country can become the world's arms dealer. Profiting from defense spending.